Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

GS-US-540-5774, 10 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 suggested
  • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
the primary endpoint was not meet, no odds ratio is reported because theproportional odds assumption was not met
GS-US-540-5774, 5 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif
  • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 53 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).